Automated Author ProfileRichter, S.
Richter, S.
Current S-Index
Sum of Dataset Indices for all datasets
Average Dataset Index per Dataset
Average Dataset Index per dataset
Total Datasets
Total datasets for this author
Average FAIR Score
Average FAIR Score per dataset
Total Citations
Total citations to the author's datasets
Total Mentions
Total mentions of the author's datasets
S-Index Interpretation
The S-Index (Sharing Index) is a comprehensive metric that represents the cumulative impact of all your datasets. It is calculated as the sum of Dataset Index scores across all your claimed datasets.
What it means:
- A higher S-index indicates greater overall impact of your datasets relative to typical datasets in their fields of research
- The S-Index grows as you add more datasets or as existing datasets gain more citations and mentions
- It provides a single number to track your research data impact over time
Current S-Index: 4.4 (sum of 7 datasets Dataset Index scores)
More information here.
S-Index Over Time
Cumulative Citations Over Time
Cumulative Mentions Over Time
Datasets
Background: Data on institutional structures of sarcoma care in Germany are scarce. The utilization of an interdisciplinary tumor board (IDTB) is an essential part of modern cancer care. We investigated to which extent and when IDTB are used in sarcoma care. We hypothesized that IDTB before treatment initiation were used more often at certified cancer centers and at high-volume centers and that IDTB utilization increased over time. Methods: From 2017 to 2020 we conducted a prospective cohort study, undertaking major efforts to include the whole spectrum of sarcoma treatment facilities. To analyze potential predictors of IDTB utilization, we calculated multivariable logistic regressions. Results: Patients and survivors (n = 1,309) from 39 study centers (22 tertiary referral hospitals, 9 other hospitals, and 8 office-based practices) participated; 88.3% of the patients were discussed at some stage of their disease in an IDTB (56.1% before treatment, 78% after therapy, and 85.9% in metastatic disease). Hypotheses were confirmed regarding the utilization of IDTB in certified cancer centers (vs. all others: OR = 5.39; 95% CI 3.28–8.85) and the time of diagnosis (2018/2019 vs. until 2013: OR = 4.95; 95% CI 2.67–9.21). Conclusion:Our study adds to the evidence regarding the institutional structures of sarcoma care in Germany. Utilization of a tumor board before therapy seems to be in an implementation process that is making progress but is far from complete. Certification is a possible tool to accelerate this development.
Authors
- Eichler, M. ;
- Andreou, D. ;
- Golcher, H. ;
- Hentschel, L. ;
- Richter, S. ;
- Hohenberger, P. ;
- Kasper, B. ;
- Pink, D. ;
- Jakob, J. ;
- Ashmawy, H. ;
- Hettmer, S. ;
- Tuchscherer, A. ;
- Grube, M. ;
- Heidt, V. ;
- Jentsch, C. ;
- Pablik, J. ;
- Wardelmann, E. ;
- Kreitner, K.-F. ;
- Kneser, U. ;
- Tonus, C. ;
- Wimberger, P. ;
- Schoffer, O. ;
- Reichardt, P. ;
- Wartenberg, M. ;
- Eberlein-Gonska, M. ;
- Bornhäuser, M. ;
- Schmitt, J. ;
- Schuler, M.K.
Background: Data on institutional structures of sarcoma care in Germany are scarce. The utilization of an interdisciplinary tumor board (IDTB) is an essential part of modern cancer care. We investigated to which extent and when IDTB are used in sarcoma care. We hypothesized that IDTB before treatment initiation were used more often at certified cancer centers and at high-volume centers and that IDTB utilization increased over time. Methods: From 2017 to 2020 we conducted a prospective cohort study, undertaking major efforts to include the whole spectrum of sarcoma treatment facilities. To analyze potential predictors of IDTB utilization, we calculated multivariable logistic regressions. Results: Patients and survivors (n = 1,309) from 39 study centers (22 tertiary referral hospitals, 9 other hospitals, and 8 office-based practices) participated; 88.3% of the patients were discussed at some stage of their disease in an IDTB (56.1% before treatment, 78% after therapy, and 85.9% in metastatic disease). Hypotheses were confirmed regarding the utilization of IDTB in certified cancer centers (vs. all others: OR = 5.39; 95% CI 3.28–8.85) and the time of diagnosis (2018/2019 vs. until 2013: OR = 4.95; 95% CI 2.67–9.21). Conclusion:Our study adds to the evidence regarding the institutional structures of sarcoma care in Germany. Utilization of a tumor board before therapy seems to be in an implementation process that is making progress but is far from complete. Certification is a possible tool to accelerate this development.
Authors
- Eichler, M. ;
- Andreou, D. ;
- Golcher, H. ;
- Hentschel, L. ;
- Richter, S. ;
- Hohenberger, P. ;
- Kasper, B. ;
- Pink, D. ;
- Jakob, J. ;
- Ashmawy, H. ;
- Hettmer, S. ;
- Tuchscherer, A. ;
- Grube, M. ;
- Heidt, V. ;
- Jentsch, C. ;
- Pablik, J. ;
- Wardelmann, E. ;
- Kreitner, K.-F. ;
- Kneser, U. ;
- Tonus, C. ;
- Wimberger, P. ;
- Schoffer, O. ;
- Reichardt, P. ;
- Wartenberg, M. ;
- Eberlein-Gonska, M. ;
- Bornhäuser, M. ;
- Schmitt, J. ;
- Schuler, M.K.
Introduction: Medical care of soft-tissue sarcoma (STS) and bone sarcoma (BS) patients in Germany has rarely been investigated. The objectives of this article were (1) to investigate medical care and survival in STS and BS patients, and (2) to examine methodological aspects of corresponding analyses based on administrative healthcare data. Methods: We analyzed data from a statutory health insurance located in Saxony, Germany, covering approximately 2 million individuals. We identified incident STS and BS patients in the period 2012–2016 using 4 different case definitions. We examined treatment rates and visits to medical oncologists and medical practices descriptively, and then compared results between case definitions. We investigated survival prospects using a relative survival analysis and estimated hazard ratios (HRs) for risk factors for mortality using Cox regression. Results: Across case definitions, the number of included sarcoma patients (STS: n = 871–1,757; BS: n = 216–689) and applied treatments (STS: 42.2–83.1%; BS: 28.3–77.8%) varied substantially. Irrespective of the case definition, the minority of patients visited medical oncologists (STS: 9.8–10.8% BS: 4.4–7.9%) and “experienced” medical practices (STS: 27.7–38.4%; BS: 18.3–23.6%). Survival prospects were better for patients who visited “experienced” medical practices (STS: HR = 0.55; BS: HR = 0.42). Conclusion: Treatment rates clearly <100% and evidence from survival analyses indicate the potential for improvements in the care of sarcoma patients in Germany, e.g., by physicians in “experienced” medical practices.
Authors
- Schoffer, O. ;
- Roessler, M. ;
- Datzmann, T. ;
- Andreou, D. ;
- Jakob, J. ;
- Eichler, M. ;
- Richter, S. ;
- Schuler, M.K. ;
- Schmitt, J.
Introduction: Medical care of soft-tissue sarcoma (STS) and bone sarcoma (BS) patients in Germany has rarely been investigated. The objectives of this article were (1) to investigate medical care and survival in STS and BS patients, and (2) to examine methodological aspects of corresponding analyses based on administrative healthcare data. Methods: We analyzed data from a statutory health insurance located in Saxony, Germany, covering approximately 2 million individuals. We identified incident STS and BS patients in the period 2012–2016 using 4 different case definitions. We examined treatment rates and visits to medical oncologists and medical practices descriptively, and then compared results between case definitions. We investigated survival prospects using a relative survival analysis and estimated hazard ratios (HRs) for risk factors for mortality using Cox regression. Results: Across case definitions, the number of included sarcoma patients (STS: n = 871–1,757; BS: n = 216–689) and applied treatments (STS: 42.2–83.1%; BS: 28.3–77.8%) varied substantially. Irrespective of the case definition, the minority of patients visited medical oncologists (STS: 9.8–10.8% BS: 4.4–7.9%) and “experienced” medical practices (STS: 27.7–38.4%; BS: 18.3–23.6%). Survival prospects were better for patients who visited “experienced” medical practices (STS: HR = 0.55; BS: HR = 0.42). Conclusion: Treatment rates clearly <100% and evidence from survival analyses indicate the potential for improvements in the care of sarcoma patients in Germany, e.g., by physicians in “experienced” medical practices.
Authors
- Schoffer, O. ;
- Roessler, M. ;
- Datzmann, T. ;
- Andreou, D. ;
- Jakob, J. ;
- Eichler, M. ;
- Richter, S. ;
- Schuler, M.K. ;
- Schmitt, J.
No description available
Authors
- H.E.S.S. Collaboration ;
- Abdalla, H. ;
- Abramowski, A. ;
- Aharonian, F. ;
- Ait Benkhali, F. ;
- Akhperjanian, A.G. ;
- Andersson, T. ;
- Anguener, E.O. ;
- Arakawa, M. ;
- Arrieta, M. ;
- Aubert, P. ;
- Backes, M. ;
- Balzer, A. ;
- Barnard, M. ;
- Becherini, Y. ;
- Becker Tjus, J. ;
- Berge, D. ;
- Bernhard, S. ;
- Bernloehr, K. ;
- Blackwell, R. ;
- Boettcher, M. ;
- Boisson, C. ;
- Bolmont, J. ;
- Bordas, P. ;
- Bregeon, J. ;
- Brun, F. ;
- Brun, P. ;
- Bryan, M. ;
- Buechele, M. ;
- Bulik, T. ;
- Capasso, M. ;
- Carr, J. ;
- Casanova, S. ;
- Cerruti, M. ;
- Chakraborty, N. ;
- Chalme-Calvet, R. ;
- Chaves R.C.G. ;
- Chen, A. ;
- Chevalier, J. ;
- Chretien, M. ;
- Coffaro, M. ;
- Colafrancesco, S. ;
- Cologna, G. ;
- Condon, B. ;
- Conrad, J. ;
- Cui, Y. ;
- Davids, I.D. ;
- Decock, J. ;
- Degrange, B. ;
- Deil, C. ;
- Devin, J. ;
- DeWilt, P. ;
- Dirson, L. ;
- Djannati-Atai, A. ;
- Domainko, W. ;
- Donath, A. ;
- Drury L.O'C. ;
- Dutson, K. ;
- Dyks, J. ;
- Edwards, T. ;
- Egberts, K. ;
- Eger, P. ;
- Ernenwein, J.-P. ;
- Eschbach, S. ;
- Farnier, C. ;
- Fegan, S. ;
- Fernandes, M.V. ;
- Fiasson, A. ;
- Fontaine, G. ;
- Foerster, A. ;
- Funk, S. ;
- Fuessling, M. ;
- Gabici, S. ;
- Gajdus, M. ;
- Gallant, Y.A. ;
- Garrigoux, T. ;
- Giavitto, G. ;
- Giebels, B. ;
- Glicenstein, J.F. ;
- Gottschall, D. ;
- Goyal, A. ;
- Grondin, M.-H. ;
- Hahn, J. ;
- Haupt, M. ;
- Hawkes, J. ;
- Heinzelmann, G. ;
- Henri, G. ;
- Hermann, G. ;
- Hervet, O. ;
- Hinton, J.A. ;
- Hofmann, W. ;
- Hoischen, C. ;
- Holler, M. ;
- Horns, D. ;
- Ivascenko, A. ;
- Iwasaki, H. ;
- Jacholkowska, A. ;
- Jamrozy, M. ;
- Janiak, M. ;
- Jankowsky, D. ;
- Jankowsky, F. ;
- Jingo, M. ;
- Jogler, T. ;
- Jouvin, L. ;
- Jung-Richardt, I. ;
- Kastendieck, M.A. ;
- Katarzynski, K. ;
- Katsuragawa, M. ;
- Katz, U. ;
- Kerszberg, D. ;
- Khangulyan, D. ;
- Khelifi, B. ;
- Kieffer, M. ;
- King, J. ;
- Klepser, S. ;
- Klochkov, D. ;
- Kluzniak, W. ;
- Kolitzus, D. ;
- Komin Nu. ;
- Kosack, K. ;
- Krakau, S. ;
- Kraus, M. ;
- Krueger, P.P. ;
- Laffon, H. ;
- Lamanna, G. ;
- Lau, J. ;
- Lees, J.-P. ;
- Lefaucheur, J. ;
- Lefranc, V. ;
- Lemiere, A. ;
- Lemoine-Goumard, M. ;
- Lenain, J.-P. ;
- Leser, E. ;
- Lohse, T. ;
- Lorentz, M. ;
- Liu, R. ;
- Lopez-Coto, R. ;
- Lypova, I. ;
- Marandon, V. ;
- Marcowith, A. ;
- Mariaud, C. ;
- Marx, R. ;
- Maurin, G. ;
- Maxted, N. ;
- Mayer, M. ;
- Meintjes, P.J. ;
- Meyer, M. ;
- A.M.W., Mitchell ;
- Moderski, R. ;
- Mohamed, M. ;
- Mohrmann, L. ;
- Mora, K. ;
- Moulin, E. ;
- Murach, T. ;
- Nakashima, S. ;
- De Naurois, M. ;
- Niederwanger, F. ;
- Niemiec, J. ;
- Oakes, L. ;
- O'Brien, P. ;
- Odaka, H. ;
- Oettl, S. ;
- Ohm, S. ;
- Ostrowski, M. ;
- Oya, I. ;
- Padovani, M. ;
- Panter, M. ;
- Parsons, R.D. ;
- Paz Arribas, M. ;
- Pekeur, N.W. ;
- Pelletier, G. ;
- Perennes, C. ;
- Petrucci, P.-O. ;
- Peyaud, B. ;
- Piel, Q. ;
- Pita, S. ;
- Poon, H. ;
- Prokhorov, D. ;
- Prokoph, H. ;
- Puehlhofer, G. ;
- Punch, M. ;
- Quirrenbach, A. ;
- Raab, S. ;
- Reimer, A. ;
- Reimer, O. ;
- Renaud, M. ;
- De Los Reyes, R. ;
- Richter, S. ;
- Rieger, F. ;
- Romoli, C. ;
- Rowell, G. ;
- Rudak, B. ;
- Rulten, C.B. ;
- Sahakian, V. ;
- Saito, S. ;
- Salek, D. ;
- Sanchez, D.A. ;
- Santangelo, A. ;
- Sasaki, M. ;
- Schlickeiser, R. ;
- Schuessler, F. ;
- Schulz, A. ;
- Schwanke, U. ;
- Schwemmer, S. ;
- Seglar-Arroyo, M. ;
- Settimo, M. ;
- Seyffert, A.S. ;
- Shafi, N. ;
- Shilon, I. ;
- Simoni, R. ;
- Sol, H. ;
- Spanier, F. ;
- Spengler, G. ;
- Spies, F. ;
- Stawarz, L. ;
- Steenkamp, R. ;
- Stegmann, C. ;
- Stycz, K. ;
- Sushch, I. ;
- Takahashi, T. ;
- Tavernet, J.-P. ;
- Tavernier, T. ;
- Taylor, A.M. ;
- Terrier, R. ;
- Tibaldo, L. ;
- Tiziani, D. ;
- Tluczykont, M. ;
- Trichard, C. ;
- Tsuji, N. ;
- Tuffs, R. ;
- Uchiyama, Y. ;
- Van Der Walt, D.J. ;
- Van Eldik, C. ;
- Van Rensburg, C. ;
- Van Soelen, B. ;
- Vasileiadis, G. ;
- Veh, J. ;
- Venter, C. ;
- Viana, A. ;
- Vincent, P. ;
- Vink, J. ;
- Voisin, F. ;
- Voelk, H.J. ;
- Vuillaume, T. ;
- Wadiasingh, Z. ;
- Wagner, S.J. ;
- Wagner, P. ;
- Wagner, R.M. ;
- White, R. ;
- Wierzcholska, A. ;
- Willmann, P. ;
- Woernlein, A. ;
- Wouters, D. ;
- Yang, R. ;
- Zabalza, V. ;
- Zaborov, D. ;
- Zacharias, M. ;
- Zanin, R. ;
- Zdziarski, A.A. ;
- Zech, A. ;
- Zefi, F. ;
- Ziegler, A. ;
- Zywucka, N.
An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
Authors
- Martin, R. ;
- Jager, A. ;
- Bohl, M. ;
- Richter, S. ;
- Fedorov, R. ;
- Manstein, D.J. ;
- Gutzeit, H.O. ;
- Knolker, H.-J.
An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
Authors
- Kiriy, N. ;
- Kiriy, A. ;
- Bocharova, V. ;
- Stamm, M. ;
- Richter, S. ;
- Plotner, M. ;
- Fischer, W.-J. ;
- Krebs, F.C. ;
- Senkovska, I. ;
- Adler, H.-J.